Document Detail


Global surveillance through PROTEKT: the first year.
MedLine Citation:
PMID:  12418556     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The increasing antimicrobial resistance amongst bacterial pathogens causing community-acquired respiratory tract infections (CARTIs) necessitates surveillance at the local, regional, national and international levels to provide information to guide empiric antimicrobial therapy. PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is a longitudinal, global, multicenter surveillance study designed to monitor the worldwide development of antimicrobial resistance and disseminate up-to-date information via the internet to assist in the choice of empiric therapy at the local level. In this paper, the results for the first year of PROTEKT are presented from a global perspective. Streptococcus pneumoniae, followed by Haemophilus influenzae and Moraxella catarrhalis, are the principal organisms responsible for the majority of CARTIs. The global prevalence of penicillin G resistance in S. pneumoniae has risen to an alarming 36.3% (high-level resistance 22.1%, intermediate-level 14.2%) with the highest prevalence found in Asia (68%). In all regions, macrolide resistance is greater than penicillin G resistance with a global prevalence rate of 31.2%. High resistance rates were also found for tetracycline (30.5%) and co-trimoxazole (43.9%), and multiresistance was found between penicillin G, macrolides, tetracycline and co-trimoxazole. The prevalence of beta-lactamase-producing H. influenzae and M. catarrhalis was found to be similar to previous reports. Macrolide resistance in S. pyogenes was 0.3% overall. Telithromycin demonstrated excellent in vitro activity against all organisms and is a potential new candidate for the empiric therapy of CARTIs. The first year of PROTEKT has provided valuable information on the prevalence of antimicrobial resistance of bacterial agents causing CARTIs that can be used for guiding empiric therapy and policies. The rapidly developing and geographically varying resistance observed in this study further emphasizes the need for accurate up-to-date surveillance data.
Authors:
R N Grüneberg
Related Documents :
8585736 - Resistance to ceftriaxone and other beta-lactams in bacteria isolated in the community....
12374386 - New anti-mrsa and anti-vre carbapenems; synthesis and structure-activity relationships ...
11688536 - The oxazolidinones as a new family of antimicrobial agent.
8346736 - Emergence of antimicrobial resistance in gram-negative bacilli causing bacteremia durin...
22966046 - Escherichia coli isolates that carry vat, fyua, chua, and yfcv efficiently colonize the...
9117036 - Pcr ribotyping and endonuclease subtyping in the epidemiology of burkholderia cepacia i...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of chemotherapy (Florence, Italy)     Volume:  14 Suppl 3     ISSN:  1120-009X     ISO Abbreviation:  J Chemother     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-11-06     Completed Date:  2003-03-12     Revised Date:  2009-08-04    
Medline Journal Info:
Nlm Unique ID:  8907348     Medline TA:  J Chemother     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  9-16     Citation Subset:  IM    
Affiliation:
GR Micro Limited, London, UK. rn.gruneberg@grmicro.co.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Anti-Bacterial Agents / pharmacology
Community-Acquired Infections / drug therapy,  epidemiology*,  microbiology*
Drug Resistance, Bacterial*
Gram-Negative Bacterial Infections / drug therapy,  epidemiology,  microbiology
Humans
Information Dissemination
International Cooperation
Internet
Ketolides*
Longitudinal Studies
Macrolides*
Microbial Sensitivity Tests
Population Surveillance / methods*
Prospective Studies
Respiratory Tract Infections / drug therapy,  epidemiology*,  microbiology*
Streptococcal Infections / drug therapy,  epidemiology,  microbiology
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Ketolides; 0/Macrolides; 0/telithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rat hindlimb unloading: Soleus and Extensor Digitorum Longus histochemistry, mitochondrial DNA conte...
Next Document:  What can PROTEKT tell us at a local level?